To highlight the role of azacytidine (AZA) in patients with myeloproliferative neoplasms developing blast phase (MPN-BP), we evaluated retrospectively 19 patients [M/F 15/4, median age 71.3 years, interquartile range (IQR) 64.5-77.7] reported in the database of our cooperative group. Median time from diagnosis to BP evolution was 52.7 months (IQR 11.2-181.8). All patients were treated with AZA at the standard dosage of 75mg/m(2). Two patients died early after 5-AZA initiation from pulmonary fungal infection and respiratory failure respectively, 4 patients had a disease progression, 4 patients a stable disease, 3 patients had an hematological improvement, 1 patient a partial response and 5 pts (26.3%) a complete response (CR) after 4, 4, 4, 5, and 12 months. The median cumulative survival from BP evolution was 9.9 months (95%CI 6.6-13.1): the comparison with an historical cohort of 72 patients with MPN-BP treated with approaches other than AZA (median cumulative survival 3.1 months, 95%CI 1.1-5.0) showed a significant advantage for patients treated with AZA (p=0.02). Our data confirm the relative efficacy and safety of AZA in this group of patients with otherwise dismal prognosis, underlining the possible achievement of long-lasting responses in a sizeable portion of them.

Andriani, A., Montanaro, M., Voso, M.t., Villivà, N., Ciccone, F., Andrizzi, C., et al. (2015). Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. LEUKEMIA RESEARCH, 39(8), 801-4 [10.1016/j.leukres.2015.03.001].

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN

VOSO, MARIA TERESA;DI VEROLI, AMBRA;
2015-08-01

Abstract

To highlight the role of azacytidine (AZA) in patients with myeloproliferative neoplasms developing blast phase (MPN-BP), we evaluated retrospectively 19 patients [M/F 15/4, median age 71.3 years, interquartile range (IQR) 64.5-77.7] reported in the database of our cooperative group. Median time from diagnosis to BP evolution was 52.7 months (IQR 11.2-181.8). All patients were treated with AZA at the standard dosage of 75mg/m(2). Two patients died early after 5-AZA initiation from pulmonary fungal infection and respiratory failure respectively, 4 patients had a disease progression, 4 patients a stable disease, 3 patients had an hematological improvement, 1 patient a partial response and 5 pts (26.3%) a complete response (CR) after 4, 4, 4, 5, and 12 months. The median cumulative survival from BP evolution was 9.9 months (95%CI 6.6-13.1): the comparison with an historical cohort of 72 patients with MPN-BP treated with approaches other than AZA (median cumulative survival 3.1 months, 95%CI 1.1-5.0) showed a significant advantage for patients treated with AZA (p=0.02). Our data confirm the relative efficacy and safety of AZA in this group of patients with otherwise dismal prognosis, underlining the possible achievement of long-lasting responses in a sizeable portion of them.
ago-2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Azacytidine; Blastic phase; MPN
Andriani, A., Montanaro, M., Voso, M.t., Villivà, N., Ciccone, F., Andrizzi, C., et al. (2015). Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. LEUKEMIA RESEARCH, 39(8), 801-4 [10.1016/j.leukres.2015.03.001].
Andriani, A; Montanaro, M; Voso, Mt; Villivà, N; Ciccone, F; Andrizzi, C; De Gregoris, C; DI VEROLI, A; Maurillo, L; Alimena, G; Latagliata, R...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Andriani et al.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 417.96 kB
Formato Adobe PDF
417.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/114924
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 24
social impact